Abeona Therapeutics Azioni (NASDAQ: ABEO)

Ultime notizie per Abeona Therapeutics (NASDAQ:ABEO) Azioni

Abeona Therapeutics

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel AIM.

Abeona Therapeutics Inc

ABEONA THERAPEUTICS ORD

Cantor Fitzgerald analyst Kristen Kluska reiterates Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Overweight and maintains $18 price target.

News

Price Target

Reiteration

Analyst Ratings

ABEO

Cantor Fitzgerald Reiterates Overweight on Abeona Therapeutics, Maintains $18 Price Target

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy and maintains $15 price target.

HC Wainwright & Co. Reiterates Buy on Abeona Therapeutics, Maintains $15 Price Target

If pz-cel receives U.S. marketing approval, this code will allow for efficient and accurate documentation, billing, and analysis of inpatient hospital procedures using pz-cel. The code will go into effect on October 1, 2024.

Biotech

Health Care

General

The Centers For Medicare And Medicaid Services Has Granted A Product-specific Procedure Code Icd-10-PCS For Abeona Therapeutics' Prademagene Zamikeracel (Pz-cel), Investigational Autologous Cell-based Gene Therapy Currently In Development For Recessive Dystrophic Epidermolysis Bullosa

WIIM

Abeona Therapeutics shares are trading higher after the company reported better-than-expected Q2 EPS results.

Earnings

Earnings Beats

Abeona Therapeutics Q2 EPS $(0.26) Beats $(0.36) Estimate, Cash Balance $123M

Abeona Therapeutics Concludes Type A Meeting With FDA To Align On Upcoming Pz-cel BLA Resubmission, Continues To Expect To Resubmit BLA In Second Half Of 2024

Under the terms of the agreement, Beacon will have the right to evaluate, for a 12-month period, the AAV204 capsid for potential use in certain ophthalmology indications, with an option to take a worldwide, non-exclusive license to use AAV204 in connection with up to five gene or disease targets. Beacon will also have the right to use AAV204 for up to four additional nominated gene or disease targets subject to certain conditions. Under the agreement, Abeona will receive an upfront payment upon Beacon&#39;s exercise of its option to license AAV204, with additional payments upon the achievement of certain development, regulatory, and sales milestones, along with tiered royalties on worldwide net sales for licensed products incorporating AAV204. Beacon will be responsible for the development and commercialization of all licensed products. The targets for which Beacon would receive rights under its non-exclusive license agreement are distinct from those currently in development at Abeona.

Contracts

Abeona Therapeutics And Beacon Therapeutics Announced An Agreement By Which Beacon Will Evaluate Abeona's Patented AAV204 Capsid For The Development And Commercialization Of Potential Gene Therapies For Select Ophthalmology Indications

HC Wainwright &amp; Co. analyst Raghuram Selvaraju initiates coverage on Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy rating and announces Price Target of $15.

Initiation

HC Wainwright & Co. Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $15

<h3>Gainers</h3>
<ul>
<li>MyMD Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MYMD#NASDAQ">MYMD</a>) stock rose 46.0% to $2.89 during Thursday's after-market session. The market value of their outstanding shares is at $6.6 million. </li>
<li>Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) stock moved upwards by 31.68% to $1.33. The market value of their outstanding shares is at $339.8 million. </li>
<li>China Pharma Holdings, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/CPHI#AMEX">CPHI</a>) shares moved upwards by 12.83% to $0.33. </li>
<li>BiomX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/PHGE#AMEX">PHGE</a>) stock rose 6.24% to $0.44. The market value of their outstanding shares is at $31.0 million. </li>
<li>Virios Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRI#NASDAQ">VIRI</a>) stock increased by 6.12% to $0.22. The market value of their outstanding shares is at $6.1 million. </li>
<li>Accuray (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARAY#NASDAQ">ARAY</a>) stock increased by 5.73% to $1.66. The company's market cap stands at $164.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Veeva Systems (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VEEV#NYSE">VEEV</a>) stock fell 7.8% to $179.0 during Thursday's after-market session. The company's market cap stands at $28.9 billion. The company's, Q1 earnings came out today. </li>
<li>Intelligent Bio Solutions (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INBS#NASDAQ">INBS</a>) shares fell 6.64% to $2.23. The company's market cap stands at $6.9 million. </li>
<li>Reshape Lifesciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RSLS#NASDAQ">RSLS</a>) stock decreased by 6.6% to $0.23. The market value of their outstanding shares is at $5.4 million. </li>
<li>OneMedNet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ONMD#NASDAQ">ONMD</a>) stock decreased by 6.14% to $2.45. The company's market cap stands at $58.4 million. </li>
<li>Cosmos Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COSM#NASDAQ">COSM</a>) stock fell 5.0% to $0.66. The market value of their outstanding shares is at $11.0 million. </li>
<li>Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) stock fell 4.99% to $4.0. The company's market cap stands at $164.7 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

ADAP

ARAY

COSM

CPHI

Intelligent Bio Solutions Inc. - Common Stock

INBS

MyMD Pharmaceuticals, Inc. - Common Stock

MYMD

ONMD

PHGE

RSLS

VEEV

VIRI

12 Health Care Stocks Moving In Thursday's After-Market Session

Stifel analyst Dae Gon Ha initiates coverage on Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Buy rating and announces Price Target of $21.

Stifel Initiates Coverage On Abeona Therapeutics with Buy Rating, Announces Price Target of $21

Cantor Fitzgerald analyst Kristen Kluska maintains Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) with a Overweight and lowers the price target from $28 to $21.

Cantor Fitzgerald Maintains Overweight on Abeona Therapeutics, Lowers Price Target to $21

Abeona Therapeutics shares are trading higher. The company reported Q1 financial results.

Guidance

Abeona Therapeutics Estimates That Its Current Cash And Cash Equivalents, Restricted Cash And Short-term Investments Of $62.7M, Credit Facility, And Proceeds Of $75M From Underwritten Offering In May Is Expected To Provide Cash Runway Into 2026

Abeona Therapeutics Q1 2024 GAAP EPS $(1.16) Misses $(0.51) Estimate

Financing

Offerings

Abeona Therapeutics Prices An Underwritten Offering Of 12.28M Shares, Pre-funded Warrants To Purchase 6.1M Shares At $4.07 Per Share Or $4.0699 Per Pre-funded Warrant, With Gross Proceeds Of Approximately $75M

U.S. stocks traded higher toward the end of trading, with the S&amp;P 500 gaining more than 1% on Tuesday.
The Dow traded up 0.68% to 38,499.41 while the NASDAQ rose 1.69% to 15,711.94. The S&amp;P 500 also rose, gaining, 1.24% to 5,072.91.
Check This Out: <a href="https://www.benzinga.com/news/24/04/38376714/wall-streets-most-accurate-analysts-views-on-3-energy-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Energy Stocks With Over 3% Dividend Yields</a>
Leading and Lagging Sectors Communication services shares climbed by 2% on Tuesday.
In trading on Tuesday, materials shares fell by 0.5%.
Top Headline General Motors Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) reported better-than-expected earnings for its fiscal first quarter.
The company posted quarterly sales growth of 7.6% year-on-year to $43.01 billion, beating the analyst consensus estimate of $41.88 billion. Adjusted EPS of $2.62 beat the consensus estimate of $2.14.
General Motors projects adjusted EPS of $9.00 – $10.00 (prior $8.50 – $9.50) versus consensus of $9.08.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Hibbett, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) shares shot up 19% to $86.26 after the company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash, in a $1.1 billion transaction.</li>
<li>Shares of Oportun Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>) got a boost, surging 36% to $3.0710 after the company announced preliminary first-quarter total revenue above estimates.</li>
<li>Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares were also up, gaining 31% to $6.48 after the company entered into a collaboration with Strand Life Sciences.</li>
</ul>
Equities Trading DOWN
<ul>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) shares dropped 17% to $6.24 after the company reported first-quarter financial results and issued weak FY24 revenue outlook.</li>
<li>Shares of Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) were down 54% to $3.3950 after the company announced the FDA issued a Complete Response Letter in response to the company&#8217;s Biologics License Application for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa.</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) was down, falling 13% to $42.67 after the company reported a first-quarter earnings miss and cut its FY24 outlook.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38377428/over-10m-bet-on-this-healthcare-stock-check-out-these-4-stocks-insiders-are-buying">Over $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying</a>
Commodities In commodity news, oil traded up 1.8% to $83.36 while gold traded down 0.2% at $2,342.00.
Silver traded up 0.5% to $27.38 on Tuesday, while copper fell 0.9% to $4.4350.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.09%, London's FTSE 100 rose 0.26% while Spain's IBEX 35 Index climbed 1.70% The German DAX gained 1.55% French CAC 40 rose 0.81% while Italy's FTSE MIB Index jumped 1.89%.
The S&amp;P Global UK PMI composite index climbed to 54.0 in April from 52.8 in the previous month. The HCOB Eurozone composite PMI surged to 51.4 in April from 50.3 a month ago.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei 225 gaining 0.30%, Hong Kong's Hang Seng Index gaining 1.92%, China's Shanghai Composite falling 0.74% and India's S&amp;P BSE Sensex gaining 0.12%.
The annual inflation rate in Hong Kong fell to 2% in March from 2.1% in the prior month. The HSBC India Composite flash PMI climbed to 62.2 in April versus a final reading of 61.8 in the earlier month. The au Jibun Bank Japan Composite PMI rose to 52.6 in April compared to a final reading of 51.7 a month ago.
Economics
<ul>
<li>Sales of new single-family houses jumped 8.8% month-over-month to an annualized rate of 693,000 in March, compared to a revised 5.1% decline in February.</li>
<li>The S&amp;P Global services PMI fell to 50.9 in April, recording the weakest level in five months and missing market estimates of 52.</li>
<li>The S&amp;P Global composite PMI fell to 50.9 in April versus 52.1 a month ago.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/04/38376630/amazon-com-united-airlines-and-2-other-stocks-insiders-are-selling">Amazon.com, United Airlines And 2 Other Stocks Insiders Are Selling</a>

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

HIBB

JBLU

OPRT

PALI

Crude Oil Moves Higher; General Motors Earnings Top Views

Shares of Nucor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NUE#NYSE">NUE</a>) fell sharply during Tuesday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/news/earnings/24/04/38365860/nucor-shares-fall-after-worse-than-expected-q1-results">quarterly financial results</a>.
Nucor reported quarterly earnings of $3.46 per share which missed the analyst consensus estimate of $3.65. Quarterly sales came in at $8.14 billion, missing the analyst consensus estimate of $8.26 billion, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Nucor shares tumbled 6.5% to $179.20 on Tuesday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares jumped 100% to $0.2419 after the company announced that it has been chosen to supply its DriveMod Tuggers for industrial automation to John Deere&#8217;s operation in Dubuque, Iowa.</li>
<li>Pineapple Energy Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PEGY#NASDAQ">PEGY</a>) shares climbed 50.4% to $0.0689 after falling 10% on Monday.</li>
<li>Oportun Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>) gained 46% to $3.29 after the company announced preliminary first-quarter total revenue above estimates.</li>
<li>Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares climbed 44.3% to $7.12 after the company entered a collaboration with Strand Life Sciences.</li>
<li>KULR Technology Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KULR#NASDAQ">KULR</a>) gained 27% to $0.5683 after the company announced it delivered on an immediate basis, a power cell battery deployment order for AI-enabled drone and advanced air mobility missions in Ukraine.</li>
<li>Smart for Life, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMFL#NASDAQ">SMFL</a>) climbed 20% to $5.22.</li>
<li>HWH International Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HWH#NASDAQ">HWH</a>) rose 19.5% to $1.5307 after declining 3% on Monday.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) gained 18.7% to $9.49.</li>
<li>Hibbett, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HIBB#NASDAQ">HIBB</a>) rose 18.4% to $85.85 after the company agreed to be acquired by JD Sports Fashion for $87.50 per share in cash, in a $1.1 billion transaction.</li>
<li>SES AI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SES#NYSE">SES</a>) gained 17.4% to $1.3499.</li>
<li>SolarMax Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMXT#NASDAQ">SMXT</a>) rose 15.5% to $9.24.</li>
<li>FuelCell Energy, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FCEL#NASDAQ">FCEL</a>) gained 15.5% to $0.9295.</li>
<li>Carmell Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTCX#NASDAQ">CTCX</a>) climbed 15.2% to $2.20.</li>
<li>Azitra, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AZTR#NYSE">AZTR</a>) shares gained 15% to $0.2244 after the company announced new preclinical data will be presented at the American Society of Gene and Cell Therapy meeting.</li>
<li>Virgin Galactic Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NASDAQ">SPCE</a>) jumped 14.4% to $0.8603.</li>
<li>9F Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JFU#NASDAQ">JFU</a>) rose 14.3% to $3.29.</li>
<li>Canaan Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CAN#NASDAQ">CAN</a>) gained 14% to $1.05. The company executives announced intentions to purchase at least $2 million of the company's common stock.</li>
<li>Cartesian Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RNAC#NASDAQ">RNAC</a>) jumped 12.7% to $20.59 after Leerink Partners initiated coverage on the stock with an Outperform rating and announced a $39 price target.</li>
<li>Spotify Technology S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPOT#NYSE">SPOT</a>) gained 12.3% to $305.73 following first-quarter financial results.</li>
<li>Heron Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HRTX#NASDAQ">HRTX</a>) climbed 11.6% to $2.89 after Capital One initiated coverage on the stock with an Overweight rating and $6 price target.</li>
<li>Mesoblast Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MESO#NASDAQ">MESO</a>) gained 9.4% to $6.05.</li>
<li>Ryder System, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/R#NYSE">R</a>) rose 9% to $118.82 following better-than-expected quarterly earnings.</li>
<li>Bloom Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BE#NYSE">BE</a>) jumped 8.8% to $10.15.</li>
<li>HealthStream, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HSTM#NASDAQ">HSTM</a>) surged 7.4% to $25.91 following upbeat quarterly results.</li>
<li>Cidara Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDTX#NASDAQ">CDTX</a>) shares rose 7% to $0.55 following upbeat quarterly results.</li>
<li>Roku, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>) gained 6.2% to $62.20.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) fell 48.4% to $3.7950 after the company announced the FDA issued a Complete Response Letter in response to the company&#8217;s Biologics License Application for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa.</li>
<li>Greenwave Technology Solutions, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GWAV#NASDAQ">GWAV</a>) shares fell 44.6% to $0.0699. Greenwave Technology Solutions disclosed that it further strengthened its balance sheet by approximately $12 million.</li>
<li>Lichen China Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LICN#NASDAQ">LICN</a>) fell 44.4% to $0.5450.</li>
<li>Tungray Technologies Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRSG#NASDAQ">TRSG</a>) shares declined 34.2% to $4.87 after gaining 24% on Monday.</li>
<li>Tian Ruixiang Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TIRX#NASDAQ">TIRX</a>) fell 26.3% to $0.5091.</li>
<li>Moolec Science SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLEC#NASDAQ">MLEC</a>) fell 24.3% to $1.87. On April 22, Moolec Science said it received approval for its plant-grown animal proteins.</li>
<li>YY Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YYGH#NASDAQ">YYGH</a>) fell 22.4% to $2.25 after tumbling over 27% on Monday. The company, last week, priced its IPO at $4 per share.</li>
<li>Top Wealth Group Holding Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWG#NASDAQ">TWG</a>) dipped 19.7% to $2.0899.</li>
<li>Comstock Holding Companies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHCI#NASDAQ">CHCI</a>) declined 18.8% to $6.44.</li>
<li>SuperCom Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPCB#NASDAQ">SPCB</a>) dipped 18% to $0.2369. SuperCom recently reported better-than-expected quarterly results.</li>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) declined 16.2% to $6.29 after the company reported first-quarter financial results and issued worse-than-expected Q2 and FY24 Revenue outlook.</li>
<li>MSCI Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MSCI#NYSE">MSCI</a>) declined 13% to $448.01 following first-quarter financial results.</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) fell 12.6% to $42.78 after the company reported a first-quarter earnings miss and cut its FY24 outlook.</li>
<li>Simpson Manufacturing Co., Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSD#NYSE">SSD</a>) dipped 11.7% to $163.40 following weak quarterly earnings.</li>
<li>Jaguar Health, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) shares fell 11.2% to $0.1598 after the company filed for a mixed shelf offering of up to $75 million.</li>
<li>Xerox Holdings Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XRX#NASDAQ">XRX</a>) tumbled 11.1% to $14.60 after the company reported worse-than-expected first-quarter results and reiterated FY24 guidance.</li>
<li>T2 Biosystems, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTOO#NASDAQ">TTOO</a>) declined 10.4% to $2.83 after gaining around 7% on Monday.</li>
<li>Sasol Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SSL#NYSE">SSL</a>) shares fell 10.1% to $7.13 after the company issued its production and sales performance metrics for the nine months ended 31 March, 2024.</li>
<li>Complete Solaria, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CSLR#NASDAQ">CSLR</a>) fell 9.3% to $0.3530 after dipping around 14% on Monday.</li>
<li>Cleveland-Cliffs Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>) dipped 7.8% to $19.22 after the company&#8217;s reported worse-than-expected first-quarter financial results.</li>
<li>Phio Pharmaceuticals Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PHIO#NASDAQ">PHIO</a>) fell 7.1% to $0.77. Phio Pharmaceuticals shares jumped around 33% on Monday after the company announced that its intratumoral injection of murine PH-762 inhibited tumor growth in murine tumor models and may generate memory-specific T cells.</li>
<li>Calix, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CALX#NYSE">CALX</a>) shares fell 4.1% to $28.34 after the company reported mixed first-quarter financial results and issued second-quarter guidance below estimates.</li>
</ul>
Read More: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38379861/bitcoin-surpasses-66-000-akash-network-core-among-top-gainers">Bitcoin Surpasses $66,000; Akash Network, Core Among Top Gainers</a>

AZTR

CALX

CDTX

CHCI

CSLR

CTCX

FCEL

GWAV

HRTX

HSTM

JAGX

KULR

LICN

MESO

MLEC

MSCI

PEGY

PHIO

RNAC

ROKU

SMFL

SMXT

SPCB

SPCE

SPOT

TIRX

TRSG

TTOO

YYGH

Why Nucor Shares Are Trading Lower? Here Are Other Stocks Moving In Tuesday's Mid-Day Session

<h3>Gainers</h3>
<ul>
<li>VolitionRX (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/VNRX#AMEX">VNRX</a>) shares rose 33.6% to $0.8 during Tuesday's regular session. The market value of their outstanding shares is at $65.7 million. </li>
<li>Palisade Bio (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) stock increased by 29.81% to $6.4. The company's market cap stands at $5.4 million. </li>
<li>Kintara Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KTRA#NASDAQ">KTRA</a>) shares increased by 24.67% to $0.14. The market value of their outstanding shares is at $5.5 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares increased by 23.88% to $1.55. The company's market cap stands at $6.8 million. </li>
<li>BIMI Intl Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIMI#NASDAQ">BIMI</a>) stock moved upwards by 23.21% to $1.38. The market value of their outstanding shares is at $19.3 million. </li>
<li>NKGen Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NKGN#NASDAQ">NKGN</a>) shares moved upwards by 20.4% to $1.77. The company's market cap stands at $40.3 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Abeona Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) shares decreased by 52.3% to $3.51 during Tuesday's regular session. The company's market cap stands at $96.0 million. </li>
<li>Rezolute (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLT#NASDAQ">RZLT</a>) stock decreased by 16.97% to $2.94. The market value of their outstanding shares is at $117.9 million. </li>
<li>Jaguar Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JAGX#NASDAQ">JAGX</a>) stock decreased by 13.57% to $0.16. The company's market cap stands at $44.6 million. </li>
<li>Adlai Nortye (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ANL#NASDAQ">ANL</a>) stock declined by 13.25% to $12.51. The market value of their outstanding shares is at $461.6 million. </li>
<li>Sunshine Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SBFM#NASDAQ">SBFM</a>) shares decreased by 12.74% to $1.26. The market value of their outstanding shares is at $1.2 million. </li>
<li>Portage Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRTG#NASDAQ">PRTG</a>) stock fell 12.49% to $0.26. The company's market cap stands at $5.1 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BIMI

Kintara Therapeutics, Inc. - Common Stock

KTRA

NKGN

PRTG

PTIX

RZLT

SBFM

VNRX

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Tuesday.
The Dow traded up 0.60% to 38,470.94 while the NASDAQ rose 1.44% to 15,673.22. The S&amp;P 500 also rose, gaining, 1.08% to 5,064.48.
Check This Out: <a href="https://www.benzinga.com/news/24/04/38376714/wall-streets-most-accurate-analysts-views-on-3-energy-stocks-with-over-3-dividend-yields">Wall Street&#8217;s Most Accurate Analysts&#8217; Views On 3 Energy Stocks With Over 3% Dividend Yields</a>
Leading and Lagging Sectors Communication services shares climbed by 1.7% on Tuesday.
In trading on Tuesday, materials shares fell by 0.8%.
Top Headline
The S&amp;P Global services PMI fell to 50.9 in April, recording the weakest level in five months and missing market estimates of 52.
Equities Trading UP 
<ul>
<li>Cyngn Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYN#NASDAQ">CYN</a>) shares shot up 70% to $0.2030 after the company announced that it has been chosen to supply its DriveMod Tuggers for industrial automation to John Deere&#8217;s operation in Dubuque, Iowa.</li>
<li>Shares of Oportun Financial Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPRT#NASDAQ">OPRT</a>) got a boost, surging 36% to $3.0503 after the company announced preliminary first-quarter total revenue above estimates.</li>
<li>Palisade Bio, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PALI#NASDAQ">PALI</a>) shares were also up, gaining 26% to $6.18 after the company entered into a collaboration with Strand Life Sciences.</li>
</ul>
Equities Trading DOWN
<ul>
<li>JetBlue Airways Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JBLU#NASDAQ">JBLU</a>) shares dropped 17% to $6.27 after the company reported first-quarter financial results and issued weak FY24 revenue outlook.</li>
<li>Shares of Abeona Therapeutics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABEO#NASDAQ">ABEO</a>) were down 49% to $3.7799 after the company announced the FDA issued a Complete Response Letter in response to the company&#8217;s Biologics License Application for pz-cel for the treatment of patients with recessive dystrophic epidermolysis bullosa.</li>
<li>LKQ Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LKQ#NASDAQ">LKQ</a>) was down, falling 13% to $42.33 after the company reported a first-quarter earnings miss and cut its FY24 outlook.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/04/38377428/over-10m-bet-on-this-healthcare-stock-check-out-these-4-stocks-insiders-are-buying">Over $10M Bet On This Healthcare Stock? Check Out These 4 Stocks Insiders Are Buying</a>
Commodities In commodity news, oil traded up 0.9% to $82.66 while gold traded down 0.6% at $2,333.00.
Silver traded down 0.1% to $27.21 on Tuesday, while copper fell 1.3% to $4.4175.
Euro zone
European shares were higher today. The eurozone's STOXX 600 rose 1.05%, London's FTSE 100 rose 0.25% while Spain's IBEX 35 Index climbed 1.58% The German DAX gained 1.46% French CAC 40 rose 0.76% while Italy's FTSE MIB Index jumped 1.78%.
The S&amp;P Global UK PMI composite index climbed to 54.0 in April from 52.8 in the previous month. The HCOB Eurozone composite PMI surged to 51.4 in April from 50.3 a month ago.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei 225 gaining 0.30%, Hong Kong's Hang Seng Index gaining 1.92%, China's Shanghai Composite falling 0.74% and India's S&amp;P BSE Sensex gaining 0.12%.
The annual inflation rate in Hong Kong fell to 2% in March from 2.1% in the prior month. The HSBC India Composite flash PMI climbed to 62.2 in April versus a final reading of 61.8 in the earlier month. The au Jibun Bank Japan Composite PMI rose to 52.6 in April compared to a final reading of 51.7 a month ago.
Economics
<ul>
<li>Sales of new single-family houses jumped 8.8% month-over-month to an annualized rate of 693,000 in March, compared to a revised 5.1% decline in February.</li>
<li>The S&amp;P Global services PMI fell to 50.9 in April, recording the weakest level in five months and missing market estimates of 52.</li>
<li>The S&amp;P Global composite PMI fell to 50.9 in April versus 52.1 a month ago.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/04/38376630/amazon-com-united-airlines-and-2-other-stocks-insiders-are-selling">Amazon.com, United Airlines And 2 Other Stocks Insiders Are Selling</a>

Dow Jumps Over 200 Points; US Services PMI Falls In April

Abeona inks research deal for gene therapy tech

Analyst Ram Selvaraju of H.C. Wainwright reiterated a Buy rating on Abeona Therapeutics (ABEO – Research Report), retaining the price target of $15...

Abeona Therapeutics: Strong Buy Rating on Strategic Partnerships and Clinical Advancements

Abeona: BLA Resubmission Of Pz-Cel Gets Ball Rolling Towards Other Milestones

Which stocks are best to buy now? According to Top Wall Street Analysts, the three stocks listed below are Strong Buys. Each stock received a new B...

3 Best Stocks to Buy Now, 7/15/2024, According to Top Analysts

Abeona Therapeutics GAAP EPS of -$0.26 beats by $0.10

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Abeona Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/abeo-stock-quote/">ABEO</a>) just reported results for the second quarter of 2024.<ul><li>Abeona Therapeutics reported earnings per share of -26 cents. This was above the analyst estimate for EPS of -36 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/abeo-stock-earnings-abeona-therapeutics-for-q2-of-2024/">ABEO Stock Earnings: Abeona Therapeutics Beats EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ABEO Stock Earnings: Abeona Therapeutics Beats EPS for Q2 2024

In a report released today, Ram Selvaraju from H.C. Wainwright reiterated a Buy rating on Abeona Therapeutics (ABEO – Research Report), with a pric...

Buy Rating on Abeona Therapeutics Bolstered by Positive Medicare Decisions and FDA Approval Progress

The latest announcement is out from Abeona Therapeutics (ABEO). Abeona Therapeutics Inc. has strengthened its Board of Directors with the appointme...

Abeona Therapeutics Enhances Board with Industry Experts

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Abeona Therapeutics (ABEO – Research Report), Cycl...

Analysts Conflicted on These Healthcare Names: Abeona Therapeutics (ABEO), Cyclacel Pharmaceuticals (CYCC) and Cardinal Health (CAH)

Abeona Therapeutics Targets RDEB Market With Promising Pz-cel Therapy

BRZE

CYCC

RARE

TSHA

Press Releases

Dyadic Intl (NASDAQ: DYAI) and Proliant Health Biologicals to Launch $6 Billion Serum Albumin Market Product in 2025

Abeona Therapeutics to Present at the Stifel Virtual Cell Therapy Forum

Abeona Therapeutics and Beacon Therapeutics Announce Non-Exclusive Agreement for Beacon to Evaluate Therapeutic Potential of Abeona's Patented AAV204 Capsid for Select Ophthalmology Indications

Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Abeona Therapeutics® Reports Second Quarter 2024 Financial Results and Concludes Type A Meeting with FDA to Align on Upcoming Pz-cel BLA Resubmission

Abeona Therapeutics® Announces Favorable Medicare Reimbursement Decisions for Pz-cel

Management

Abeona Therapeutics® Announces Appointment of Bernhardt Zeiher, MD, FCCP, FACP, and Eric Crombez, MD to its Board of Directors

Comments

Abeona Therapeutics

Notizie

Ultime notizie per Abeona Therapeutics (NASDAQ:ABEO) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO